New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Lund, Sweden — 25 June 2024 — Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study[1] comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal[®]/Brixadi[®]) to daily sublingual buprenorphine/naloxone (SL-BPN/NX). The data presented suggests the effectiveness in individuals with opioid dependence who use fentanyl, consistent with the results from the Phase 3 study. “These findings are consistent with the Phase 3 data showing the effectiveness of extended-